Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)

By sjmartinez • April 25, 2025

Aggarwal R, Pongtarakulpanit N, Sullivan DI, Moghadam-Kia S, Bae SS, Wilkerson J, Saygin D, Marder G, Venuturupalli S, Dellaripa PF, Danoff SK, Doyle T, Hunninghake GM, Lee JS, Fischer A, Falk J, Johnson C, Koontz D, Ascherman DP, Oddis CV. Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD). Rheumatology (Oxford). 2025 Apr 24:keaf218. doi: 10.1093/rheumatology/keaf218. Epub ahead of print. PMID: 40272902.

Tags: abatacept, anti-synthetase syndrome, Cedars Sinai DoM, Idiopathic inflammatory myopathy, interstitial lung disease, placebo-controlled trial, Publications, Pulmonary, Critical Care & Sleep Medicine, randomized, Rheumatology

Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy

Karlsberg RP, Thummala AR, Elisarraras FX, Golub IS, Cho GW. Short-interval coronary plaque remodeling assessed by serial AI-quantified coronary CTA during intensive plaque-directed therapy. J[...]

A National Institute on Aging workshop on sex differences in health across the lifespan

Pea J, Addie S, Ambrosio F, Anderson RM, Bairey Merz CN, Barr E, Carrington-Lawrence S, de Cabo R, Desvigne-Nickens P, Dubal DB, Haakenson C, Hargove-Grimes[...]

Association between adverse pregnancy outcomes and awareness of cardiovascular risk factors: A nuMoM2b-HHS secondary analysis

Wendl EM, Allshouse AA, Goodwin A, Hobbs B, Greenland P, Levine L, Grobman W, Saade GR, Cameron N, Merz CNB, Rouse C, Rogan S, Chung[...]